RESEARCH → TCF-001 TRACK Our fully remote, decentralized precision medicine clinical trial has enrolled 157 patients with 40 rare cancers from 41 states,...
2023: An Impactful Year In Review
read more
OnTarget
A Rare Cancer Blog
Thank you to our Community Fundraisers!
February is Cholangiocarcinoma Awareness Month. We are proud to highlight the many efforts from TCF community members who are working to bring attention to...
A Meaningful Gift
From our very first days, TargetCancer Foundation has been so fortunate to be surrounded by a community of support and friendship. This community continues to...
TCF Executive Director Jim Palma to Receive the 2022 Ruesch Center Luminary Award in GI Cancers
We are incredibly proud to announce that our Executive Director Jim Palma has been named a Ruesch Center 2022 Luminary Awards in GI Cancer recipient! The...
A Snapshot of a Special Volunteer
Meet TargetCancer volunteer Gleb Budilovsky! Gleb grew up in Topsfield, MA, and moved to Boston in 2005, where he lives with his wife Lindsey and adorable dog...
Meet Jenna Hart!
Meet TargetCancer Foundation volunteer Jenna Hart. Originally from Connecticut, Jenna now lives on Boston's North Shore and is the Senior Visual Designer on...
A Reflection of Purpose After 13 years: Remembering Our Founder
Written by Kristen Palma, TargetCancer Foundation President Each year, as I sit down to write this note, I wonder what more I can say. It has been 13...
Introducing Giselle Mota, our Newest Volunteer!
We are pleased to introduce you to TargetCancer Foundation's newest volunteer, Giselle Mota. Originally from Los Angeles, CA, Giselle currently resides in...
Meet TCF Volunteer Cami Harris
Originally from Greensboro, NC, Cami Herring currently lives in Cambridge, MA with her chihuahua, Coco. Cami is a Project Analyst at Mintz working with the...
Introducing TCF Volunteer Catherine May
Originally from Dalton, MA, Catherine moved to the Boston area in 2020 after graduating from Williams College. She is a Senior Practice Coordinator at Mintz....
2022 Gala Volunteer Spotlight
As the 2022 TargetCancer Foundation Gala approaches, we are pleased to feature some of our wonderful volunteers, whose efforts are integral to the Gala's...
Honoring Our Past, Celebrating Our Progress: FDA Approves Tibsovo for Cholangiocarcinoma with IDH1 Mutation
Just a few days ago, we sent a remembrance of our founder, Paul Poth. It seems especially meaningful today to send along news of a different type- the very...
Promising New Cholangiocarcinoma Treatment Findings
An exciting paper was recently published in Cancer Discovery highlighting the promise of the recently FDA approved FGFR inhibitor drugs for an even broader...
Importance of Local Physicians at the TRACK Virtual Molecular Tumor Board
The rapid progress made over the last decade in bringing comprehensive genomic profiling to rare cancer patients has created the opportunity to significantly...
TRACK (Target Rare Cancer Knowledge) Virtual Molecular Tumor Board
The TRACK Study incorporates many features that make it unique and especially significant for rare cancer patients. One of these features is the Virtual...